Subject: Re: Invitation to a High Level Working Meeting on May 23 at the Occasion of the 70th WHA - New Opportunities to Eliminate Viral Hepatitis
From: "Graeme Robertson" <[email-masked]>
To: "David" <Sergeenko>
Cc: "Sopo" <Belkania>
Date: Tue, 9 May 2017 07:44:12 +0000

Hi David,

It is the same as we were talking about. Sorry for any
confusion.

Best wishes
Graeme

Sent from my iPhone

On 9 May 2017, at 06:51, David Sergeenko <[email-masked]<mailto:[email-masked]>> wrote:

Hello Graeme
I have got this (forwarded) invitation.
Is it the same event, we were talking or other?
Regards
David

Begin forwarded message:

From: Barbara Bulc <[email-masked]<mailto:[email-masked]>>
Date: May 9, 2017 at 09:33:08 GMT+4
To: <[email-masked]<mailto:[email-masked]>>
Cc: <[email-masked]<mailto:[email-masked]>>, <[email-masked]<mailto:[email-masked]>>, <[email-masked]<mailto:[email-masked]>>
Subject: Invitation to a High Level Working Meeting on May 23 at the Occasion of the  70th WHA -  New Opportunities to Eliminate Viral Hepatitis

Honorable Minister David Sergeenko,
We have the honour to invite you to participate in a high level working meeting on New Opportunities to Eliminate Viral Hepatitis, in Geneva on Tuesday May 23 at the occasion of the 70th World Health Assembly and the recent launch of the Global Hepatitis Report 2017. Sustainable Development Goals (SDG 3) highlight the importance of combating and elimination hepatitis.
The recent emergence of directly acting antivirals as well as affordable new diagnostics provides an opportunity to end Hepatitis C globally, and longer term Hepatitis B. However, the rapid pace of these developments means that not all key stakeholders might fully realize their potential for hepatitis elimination.
Specifically we would appreciate it if you could speak on the strategies of Georgia in pursuit of the elimination of viral hepatitis.
In keeping with this objective, the meeting will share new approaches, successes and challenges in getting value for investments to eliminate viral hepatitis and generate synergies among partners for collective action.  The dialogue will focus on three main themes:
*     Access: Availability of affordable new diagnostics and treatments
*     Investment: Resources and new approaches to increase public and private sector investments
*     Implementation: Country success factors and challenges in implementing and scaling prevention, diagnostics and treatments, policy and systems requirements, advocacy and innovation.

This high level working is co-hosted by CDA Foundation, GD Impact, Gilead and Abbott. The meeting will bring together a small group of key public and private sector actors working towards elimination of viral hepatitis, and will include Ministers of Health, and leaders from the World Health Organization (WHO) - Global Hepatitis Programme, The Global Fund, UNITAID, World Hepatitis Alliance, Center for Disease Analysis Foundation (CDA Foundation), GD Impact, Gilead Sciences and Abbott Diagnostics.

We would appreciate receiving your response to this invitation by email to Catalina Linares (email [email-masked]<mailto:[email-masked]>) by Monday, May 15.
Participation is by invitation only - the number of participants will be limited to less than 20 to enable a high level confidential dialogue. Please find the meeting agenda with other details attached.
On behalf of the co-hosts, please accept Honorable Minister David Sergeenko the assurance of our highest consideration.

Barbara Bulc
President

                    Barbara Bulc, President

                    162, Rt. de la Capite, 1244 Geneva, Switzerland
                    EU tel : +41 79 263 9627
                    US tel : +1 646 202 1464
                    [email-masked]<mailto:[email-masked]>
                    www.globaldevelopment-impact.org<http://www.globaldevelopment-impact.org/>

<SAVE THE DATE INVITATION New Opportunities to Eliminate Viral Hepatitis _May 23_2017.pdf>
DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England